Controlled ovarian hyperstimulation, combining GnRH antagonist co-treatment and GnRHa trigger, has become standard practice to eliminate the risk of severe early OHSS [6]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.